Introduction
Considerable attention has been paid to human ribonucleases (RNases) in recent years as a result of increased knowledge of their biological properties and possible therapeutic applications (Schein, 1997; Rybak and Newton, 1999) . One important feature of this family of enzymes is that some of them contain N-linked oligosaccharides.
Earlier studies showed that secretory RNase (RNase 1), the human counterpart of bovine pancreatic RNase A, contained three N-glycosylation sites and extensive glycan heterogeneity (Hitoi et al., 1987; , the composition of which depended on the organ from which the enzyme originated (Yamashita et al., 1986) . In contrast, the so-called nonsecretory RNases (RNases 2 and 3) contained unusual truncated N-glycan structures (tri-, tetra-, and pentasaccharides), which were independent of tissue origin (Lawrence et al., 1993a,b) .
Human pancreatic ribonuclease (RNase 1) is a secretory glycoprotein found in most human tissues, but mainly in the pancreas, where it is expressed by acinar cells (Futami et al., 1997; Ferna Â ndez-Salas et al., 2000; Peracaula et al., 2000) prior to secretion into the pancreatic ducts. RNase 1 is also expressed by pancreatic adenocarcinoma tissues and secreted by pancreatic adenocarcinoma cell lines, presumably of ductal origin (Ferna Â ndez-Salas et al., 2000; Peracaula et al., 2000) .
Pancreatic adenocarcinoma is one of the carcinomas with the worst prognosis and is very difficult to diagnose. It is the fourth to fifth leading cause of cancer-related mortality in Western countries (Mangray and King, 1998; Greenlee et al., 2001) . A variety of serum tumor markers, especially CA19-9, a Lewis blood group±related mucin, have been proposed for diagnosis and follow-up of this type of neoplasia, but their application remains experimental (Lillemoe et al., 2000) . The identification of a specific early tumor marker would result in substantial improvements in the survival and treatment of the patients affected by pancreatic adenocarcinoma.
RNase 1 has been detected in serum by enzymatic and immunological methods, and its elevation in pancreatic cancer suggested that it might be a useful indicator of this carcinoma. However, although RNase 1 levels in pancreatic adenocarcinoma sera are usually higher than in healthy sera, the differences are not specific enough to use the absolute amount of RNase 1 as a tumor marker (Reddi and Holland, 1976; Weickman et al., 1984; Kurihara et al., 1984; Kemmer et al., 1991; Kobayashi and Kawakubo, 1994; Tabare Âs, 2000) .
Monosaccharide composition analysis of RNase 1 glycans from healthy pancreas indicated higher levels of fucose and absence of sialic acid in comparison to RNase 1 secreted from a human pancreatic tumor cell line, Capan-1 Ferna Â ndez-Salas et al., 2000) . In addition, enzyme-linked immunosorbent assays (ELISAs) of RNase 1 from healthy pancreas and Capan-1 using anticarbohydrate antibodies (Ferna Â ndez-Salas et al., 2000) showed a differential expression of Lewis antigens in the two samples. These data suggest that the altered glycosylation of RNase 1 could permit differentiation between the RNase 1 produced by pancreatic acinar cells and the RNase 1 produced by pancreatic adenocarcinoma cells. Moreover, aberrantly glycosylated RNase 1 in serum could provide a tumor marker of pancreatic adenocarcinoma. To establish a firm analytical basis for these findings and to provide an insight into the perturbations in the levels of glycosylating enzymes in the tumor cells, a more detailed analysis of the glycosylation of normal and tumorassociated RNase 1 was performed.
Accordingly, using a combination of high-performance liquid chromatography (HPLC) and mass spectrometry (MS), we compared the oligosaccharides released from RNase 1 purified from pancreas and from two human pancreatic adenocarcinoma cell lines, Capan-1 and MDAPanc-3. The compositions of the oligosaccharide pools were completely different, suggesting that different glycosyltransferases are involved in the pancreatic tumor cell glycan processing pathways. Some of the glycosylation changes in RNase 1 correspond to blood groupErelated carbohydrate antigens, in particular the Lewis antigens. Lewis y antigen was only detected in RNase 1 from healthy pancreas. In contrast, RNase 1 from tumor cells expressed charged structures, such as sialyl-Lewis x or sialyl-Lewis a antigens, differences that could easily be identified by western blot analysis with antibodies against the Lewis structures. We present the details of the altered glycosylation pattern of RNase 1 that allow distinction between normal and a tumor situation. These findings suggest that the detection of glycosylation changes both in RNase 1 and in other serum glycoproteins secreted by carcinoma cells could be of great value in the discovery of new tumor markers.
Results
Oligosaccharide sequencing of RNase 1 glycans from pancreas: RNase 1 purification Purification of human pancreatic ribonuclease was carried out following the methods described by Weickman et al. (1981) and with slight modifications. After pancreas homogenization, two chromatographic steps were performed that ensured recovery of both neutral and charged glycoforms. Chromatography on an affinity heparin column gave several ribonuclease fractions that were then pooled and further purified by reversed-phase chromatography. Elution from the reversed-phase column yielded nine pure RNase 1 fractions (P1±P9) with ribonuclease activity detected by zymography (data not shown). These fractions differed in their electrophoretic mobility because of their different levels of glycosylation, as shown by sodium dodecyl sulfate±polyacrylamide gel electrophoresis (SDS±PAGE) ( Figure 1a±d ) and zymography (data not shown).
Pancreatic RNase 1 has three N glycosylation sites: Asn-34, Asn-76, and Asn-88. Earlier studies have shown that the Asn-34 site was invariably occupied and contained oligosaccharides with very similar compositions. In contrast, sites Asn-76 and Asn-88 were occupied in only 50% and 16% of the molecules, respectively. PNGase F digestions of these RNase 1 fractions over short time periods showed that glycoproteins of high apparent molecular mass, in which three or two glycosylation sites were occupied, digested progressively via two or one bands of intermediate mass to a 15-kDa band, corresponding to the unglycosylated RNase 1, whereas glycoproteins with one site occupied (Asn-34) were digested directly to the lowest mass band of 15 kDa (data not shown) . Fractions with apparent molecular masses ranging from 24 to 36 kDa, P1±P6 in Figure 1a±c , contained RNase 1 fractions with two or three glycosylation sites occupied and fractions P7±P9 (Figure 1c±d ) (apparent molecular masses lower than 24 kDa) correspond to RNase 1 fractions glycosylated at one site (Asn-34) only. (a±d) Coomassie blue staining of SDS±PAGE gels of the purified RNase 1 fractions from pancreas after separation by reversed-phase chromatography. (1a) Lane 1, molecular markers; lanes 3±4, fraction P1; lanes 5±6, fraction P2; lanes 7±9, fraction P3; and lane 10, unglycosylated rRNase 1 (2 mg). (1b) Lanes 1 and 10, molecular markers; lanes 3±5, fraction P4; lanes 6±8, fraction P5. (1c) Lane 1, molecular markers; lanes 3± 5, fraction P6; lanes 6±9, P8; and lane 10, unglycosylated rRNase 1 (2 mg). (1d) Lane 1, molecular markers; lanes 3±6, fraction P7; lanes 7±9, fraction P9; and lane 10, unglycosylated rRNase 1 (2 mg). The bands P1±P9 that were excised from the gel are boxed. (1e) Normal phase HPLC profile of 2AB-labeled N-linked oligosaccharides obtained by in-gel digestion of pancreatic RNase 1 fractions P1, P3, P5, P7, and P9. The different glycan peaks are numbered from 1 to 12.
Characterization of oligosaccharides: overall profiles of RNase 1 glycans from pancreas by normal phase HPLC analysis Oligosaccharides from the different electrophoretic bands of RNase 1 from normal pancreas were released by in situ digestions with PNGase F, fluorescently labeled with 2-aminobenzamide (2AB) and subjected to normal phase HPLC and both matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and liquid chromatography (LC)-electrospray (ESI) MS. From the many RNase 1 fractions analyzed, glycan profiles of only five typical examples are shown (P1, P3, P5, P7, and P9) that correspond to RNase 1 fractions with different levels of glycosylation (Figure 1e ). Glycans were analyzed on the basis of their elution positions, measured in glucose units (GU) (Guile et al., 1996) and from their masses as obtained from MALDI-TOF and LC-ESI MS. Fourteen structures with GU values from 6.8 to 10.0 (Peaks 1±12, Figure 1e and Tables I and II) were present in all HPLC fractions (P1± P9), although in varying amounts. Additional glycans with GU units from 10.3 to 14.4 were present in the more highly glycosylated RNase 1 fractions, P1±P6 (15±5%), where two or three glycosylation sites were occupied (Figure 1e ). Fractions P7±P9, in which only Asn-34 was glycosylated, contained mainly bianntenary glycans with GU values between 6.8 and 10.0. Increasing amounts of the larger glycans (with GU 4 10) were detected where Asn-76 and/or Asn-88 sites were occupied, indicating that both of these sites could accommodate larger sugars than Asn-34. As the number of occupied sites increases, so does the overall complexity of the individual glycans.
MS analysis of P3 and P9 glycans
The MALDI MS analysis of glycans from fraction P9 is shown ( Figure 2a , Table I ) together with the corresponding LC-ESI MS data. MALDI MS analysis of fraction P3 (Figure 2b, Table Ib) , which contains, in addition to the glycans found in P9, larger glycans, detected many more compounds with possible compositions as high as Hex 12 -HexNAc 11 Fuc 4 . The structural determination of the glycans was carried out by normal phase HPLC analysis of an aliquot of the glycan pools from fractions P3 (Figure 3 ) and P9 before and after digestion with exoglycosidase arrays.
Exoglycosidase sequencing of pancreas RNase 1 glycans: P3 glycans Treatment with Arthrobacter ureafaciens sialidase (ABS) did not digest any glycans from P3 (Figure 3b) , consistent with the MALDI-TOF MS data ( Figure 2b ) and with monosaccharide analysis that indicated the absence of sialic acid in pancreatic ribonuclease oligosaccharides. Treatment with almond meal a-fucosidase (AMF) (specificity for outer arm fucose linked a1-3/4 to GlcNAc) (Figure 3c ), followed by bovine kidney fucosidase (BKF) (broad specificity for a-fucoses) digested all fucosylated structures to the following neutral complex oligosaccharides ( Figure 3d ): 65±80% complex biantennary structure A 2 G 2 (see legend to Figure 2 for a description of this nomenclature); 10±18% complex bisected biantennary structures A 2 G 1 B and A 2 G 2 B; and 5±15% complex triantennary structure A 3 G 3 . Other minor structures, only found in the most highly glycosylated fractions (P1±P6), digested to A 4 G 4 . The main glycans derived from the complex biantennary glycan A 2 G 2 corresponded to highly fucosylated N-linked oligosaccharides and were present in all RNase 1 fractions. The different proportions of each glycan structure depended on the RNase 1 fraction analyzed, that is, on the number of occupied glycosylation sites.
Digestions of the defucosylated glycans from the RNase 1 fractions, with either Streptococcus pneumoniae galactosidase (SPG) (specificity for galactose linked b1-4) (Figure 3e ) or bovine testes b-galactosidase (BTG) (specificity for galactose linked b1-3/4 4 6) ( Figure 3f ) in the enzyme array, produced the same results, that is, A 2 , A 2 B, A 3 , and A 4 . This indicates that all galactose residues are linked b1-4 to GlcNAc.
Finally, treatment with S. pneumoniae b-N-acetylhexosaminidase (SPH, specificity for GlcNAc linked b1E2 4 4 to mannose) resulted in the formation of (Man) 3 (GlcNAc) 2 from A 2 structures (Figure 3g ). When A 3 structures were present, (GlcNAcb1-4)(Man) 3 (GlcNAc) 2 was also obtained as a product of incomplete digestion. The difficulty in removing the GlcNAc 1-4 attached to mannose indicated that these glycans were mainly branched on the 3-antenna. A 4 structures were digested to a glycan with a GU value of 6.13, corresponding to A 3 . Only the GlcNAc, which was linked b1-2 to the mannose of the 3-antenna, was removed, because the enzyme has difficulty removing b1-2 linked GlcNAc from a mannose to which a second GlcNAc is b1-6 linked (Yoshima et al., 1980) .
Detailed analysis of fucosylation in RNase 1 glycans from pancreas
The fucosylated structures were further characterized by sequential exoglycosidase digestion of the glycan pool using AMF (specificity for fucoses linked a1-3/4) and BKF (broad specificity for a-fucoses). AMF digested one or two fucose residues from the biantennary glycans (peaks 5, 8a, 9, 10a±b, 11, 12) (decrease in elution position of around 0.8 GU per fucose) (Figure 4b ). The triantennary glycans contained from one to three fucose residues. The fucoses were assumed to be attached to GlcNAc in the a1-3 rather than in the a1-4 position as galactose had already been linked to GlcNAc in the b1-4 position (see previous discussion). Treatment with BKF removed from one to four fucose residues linked either a1-2 to galactose or a1-6 to the internal GlcNAc (core fucose) (Figure 3d ). To establish the linkage of these fucose residues, the glycosylation pattern of a digestion with AMF BTG was compared with that from a digestion with AMF BTG BKF (Figure 4c, d) . If fucose was linked to galactose at the nonreducing termini, BTG would not be able to remove the galactose. On the other hand, if fucose was attached to outer arm GlcNAc, then digestion with AMF BTG would remove the terminal galactose residue. The structures of the major polyfucosylated peaks could then be determined. Peaks 8, 10, and 12 (Figures 1±4, Tables I and II) contained glycans with two fucoses linked a1-2 to outer arm galactose and one core fucose; peaks 6, 9, and 11 glycans had one fucose a1-2 linked to outer arm galactose, and one core fucose; and peaks 1, 5, 8 and 10 contained only one core fucose. All glycans with outer arm fucose either a1-3 or a1-2 linked Positive ion reflectron MALDI-TOF mass spectra of (a) glycans from fraction P9 and (b) fraction P3 before 2AB labeling. The spectrum in a has been processed using the Maximum Entropy deconvolution algorithm in the Micromass Mass-Lynx software, whereas that in b has been smoothed using the Savitzky Golay algorithm (10 Â 2). Peaks are labeled with their measured monoisotopic masses, except in the high mass range where average masses, indicated with an asterisk, have been used. The numbers in parentheses refer to the peak numbers in Figure 1 . Abbreviations for this and later figures: A (1±4) indicates the number of antennae linked to the trimannosyl core; G (1±4) indicates the number of terminal galactose residues in the structure; B indicates the presence of a bisecting GlcNAc; and F (1±5) indicates the number of fucose residues.
Glycosylation differences between normal and tumor RNase 1 also contained fucose linked a1-6 to the core GlcNAc, as is commonly the case (D. R. Wing, personal communication).
Summary of RNase 1 glycans from pancreas
Individual digestions of each of the glycan peaks from fraction P9 with AMF and AMF BKF and comparison of their GU values with those of highly fucosylated glycans from human parotid gland confirmed the identification of the sugars present in each of the major peaks in the normal phase HPLC profile (data not shown).
Tables I and II list all the structures determined from a combination of the normal phase HPLC, exoglycosidase digestion, MALDI MS, and LC-ESI MS data. The majority of glycans were fucosylated complex biantennary structures. Triantennary and tetrantennary fucosylated glycans were present in the highly glycosylated RNase 1 fractions (P1±P6), together with traces, detected by MALDI MS, of glycans with poly-N-acetyllactosamine chains and others having compositions of (Hex) 5 ± 8 (GlcNAc) 2 , presumed to be the high-mannose glycans ([(Man) 5 ± 8 GlcNAc] 2 , termed Man 5 ±Man 8 ) structures.
Oligosaccharide sequencing of RNase 1 glycans from the pancreatic adenocarcinoma cell line Capan-1: RNase 1 purification RNase 1 fractions were purified from Capan-1 cell culture media following the method described by Ferna Â ndez-Salas et al. (2000) with some modifications. After collection and concentration of the Capan-1 conditioned medium, RNase 1 glycosylated fractions were first purified by heparin affinity column chromatography, as in RNase 1 purification from pancreas. RNase 1 fractions were then pooled and further purified by a MONO-S cationic exchange column and a Vydac C4 reversed-phase column. Pure ribonuclease fractions eluted from reversed-phase chromatography were identified by ribonuclease activity in a zymogram , and their homogeneity was tested , from pancreas to confirm which peaks contained outer a1-2 fucose linked to galactose. One aliquot was analyzed directly by HPLC, and the remaining were treated with exoglycosidases prior to HPLC analysis as indicated. In the AMF digestion, full arrows correspond to the digestion of one fucose and dotted arrows to the digestion of two fucoses. Shaded peaks are those that contain sugars that are digested by the subsequent enzyme array. See text for enzyme abbreviations and specificities and previous legends for monosaccharide representation.
by SDS±PAGE (Figure 5a ). Glycosylated RNase1 fractions (CP2-CP5) were used for glycan analysis.
Characterization of oligosaccharides: overall profiles of RNase 1 glycans from Capan-1 by normal phase HPLC analysis RNase 1 oligosaccharides from the Capan-1 samples were released from gel bands by in situ digestion with PNGase F and fluorescently labeled with 2AB, as described for pancreatic RNase 1. As some of the lanes clearly contained more than one ribonuclease band, these different bands were excised individually. Thus, from fraction CP3, band CP3a corresponded to the upper band and CP3b corresponded to the lower band; CP4 had two upper bands (CP4a, CP4b) and one lower band (CP4c); and CP5 had two upper bands (CP5a, CP5b) and one lower band (CP5c) (see Figure 5a ). As described for pancreatic RNase 1 fractions, the different electrophoretic behavior of the RNase 1 fractions from Capan-1 reflected different levels of glycosylation. Glycosylated bands with a high apparent molecular mass had two or three glycosylation sites occupied, whereas lowapparent-molecular-mass glycosylated fractions had only one site occupied (Ferna Â ndez-Salas et al., 2000) . Thus, glycosylated fractions of apparent molecular mass higher than 24 kDa (CP2a, CP3a±b, CP4a±b, CP5a±b) contain more than one occupied glycosylated site, whereas CP4c and CP5c correspond to RNase 1 fractions with only one site occupied (Figure 5a ). Band CP5d contains unglycosylated RNase 1.
Normal phase HPLC of Capan-1 oligosaccharides showed that all these RNase 1 fractions contained glycans with GU values ranging from 6.8 to 10.0 with similar profiles (Figure 5b ). In addition, the more highly glycosylated RNase 1 bands CP2a, CP3a, CP4a, and CP5a contained a proportion of larger glycans (GU from 10 to 14). The lower bands, CP3b, CP4b, and CP5b, contained smaller amounts of these larger glycans, but none were detected in the lowest bands CP4c and CP5c.
Exoglycosidase sequencing of Capan-1 RNase 1 glycans: CP3a glycans Capan-1 RNase 1 glycan pools released from these bands were digested by exoglycosidase arrays. All the different glycan pools gave similar results, which are discussed in the following (Figure 6 ).
Analysis of sialylation in RNase 1 glycans from Capan-1 Treatment of the glycans from the Capan RNase 1 fractions (e.g., CP3a) ( Figure 6a , panel a) with ABS (broad specificity for a-sialic acids) indicated that some of the structures contained sialic acid, most markedly those with GU values around 9±10 (Figure 6a, panel b) . Digestion with Newcastle disease virus neuraminidase (specificity for a2-3 sialic acids) gave almost the same profile as that for ABS digestion, indicating that the sialic acids were predominantly a2-3 linked (data not shown). The extent of sialylation of Capan-1 RNase 1 glycans was determined by weak anion exchange chromatography, which binds charged glycans. The column was calibrated with N-glycans (neutral, monosialylated, disialylated, and trisialylated) from bovine fetuin. Most of the Capan RNase 1 glycans eluted in the void and were therefore neutral, but there were also some mono-and disialylated glycans that eluted later (data not shown). Following treatment of the pool of glycans with ABS caused all glycans to elute in the void volume, indicating that all of the charge was due to sialic acid.
Analysis of fucosylation in RNase 1 glycans from Capan-1 Further digestion of the glycans from band CP3a with AMF ( Figure 6a , panel c) indicated the presence of one or more fucose residues, linked either a1-3 or a1-4. Additional digestion with BKF removed additional fucoses (data not shown). To determine the linkage of these fucoses (i.e., whether they are outer arm fucoses linked a1-2 to galactose or a1-6 to the core GlcNAc) a digestion with ABS AMF BTG was compared with that from ABS AMF BTG BKF (Figure 6a , panels d and e). Glycans with GU ranging from 6.8 to 10 produced a Glycosylation differences between normal and tumor RNase 1 similar glycan pattern in both digestions, but with a shift of 0.4 GU units for all peaks except one (unshaded peak, Figure 6a , panel d) when the digestion contained BKF. These data indicated that this peak alone had no core fucose. The observation that all galactose residues were removed with ABS AMF BTG shows that no fucose was linked to these external galactoses in these structures, and, furthermore, the fucose residues removed with BKF corresponded to a core fucose (Figure 6a , panel e). However, glycans with GU higher than 10 contained several fucose residues that were linked either a1-2 or a1-6.
Analysis of core structures of RNase 1 glycans from Capan-1 Digestions of the glycan pool with SPG (specificity for galactose linked b1-4) (data not shown) and BTG (specificity for galactose linked b1-3/4) (Figure 6a , panel e and Figure 6b , panel a) gave slightly different results indicating the presence of galactose linked both 1-3 and 1-4). These data indicate that fucoses released by AMF were linked in both the a1-3 or 1-4 positions.
Some of the glycan structures obtained after BTG or SPG digestions, in particular the major peak at GU 5.74 ( Figure  6a , panel e and Figure 6b , panel a), appeared to contain the complex biantennary bisected glycan A 2 B. Comparing the profile of the glycans after a further digestion with either jack bean b-N-acetylhexosaminidase (JBH) or SPH showed that most of this peak was digested with SPH but not with JBH (Figure 6b , panels b and c). Digestions on standards have shown that JBH does not digest glycans with bisecting GlcNAc, whereas SPH does, consistent with the assignment of A 2 B to the major component of the peak at GU 5.74.
SPH is not very efficient at removing GlcNAc linked b1-4 to mannose but will remove a bisecting GlcNAc (as discussed). However, SPH does not digest GalNAc residues. Thus, a further digestion with JBH, which does remove GalNAc, was carried out (Figure 6b MS analysis of Capan-1 RNase 1 glycans MALDI and ESI mass spectra of the glycans from band CP5c (Figure 7 , Table III) contained several major ions with a high percentage of HexNAc. The most prominent of these had compositions of Hex 3 HexNAc 6 dHex 2 (mass 2157.8) and, particularly Hex 3 HexNAc 6 dHex 3 (mass 2303.9) (Figure 7a ). The exoglycosidase digestions had shown the presence of fucoses in these glycans, so dHex is assigned as a fucose throughout the rest of the discussion. The ESI tandem mass spectrometry (MS/MS) spectra of these compounds (see the following) contained prominent B-type fragment ions (Domon and Costello, 1988 , fragmentation nomenclature) at m/z 407.2 (Figure 8 ) corresponding to a composition of HexNAc 2 . Glycans with this composition have been found on several glycoproteins (Green et al., 1985; Green and Baenziger, 1988; Chan et al., 1991; Van-den-Eijnden et al., 1995) and contain antennae consisting of GalNAc-GlcNAc rather than Gal-GlcNAc. The inability of SPH to digest these structures, even though they were sensitive to JBH, was consistent with the presence of the terminal GalNAc residue. The amount of material available was insufficient to confirm this by gas chromatography MS. 
LC-ESI MS/MS analysis of RNase 1 glycans from
Capan-1 Further details of the structures of some of these glycans were obtained using LC-ESI MS/MS. The ESI spectrum itself (Figure 7b ) confirmed the presence of sialylated glycans, identified in the HPLC analysis. These constituted about a quarter of the total structures that had presumably fragmented under MALDI MS conditions (Harvey, 1999) , thus accounting for their absence in the reflectron-MALDI spectrum (Figure 7a) . Figures 8 and 9 show the fragmentation patterns obtained from structures with doubly charged precursor ions at m/z 1141.6 and 954.9 from fraction CP5.
The structure producing the [M 2H] 2 ion m/z 1141.6 (Hex 3 HexNAc 6 Fuc 3 ) (Figure 8 ) appears from the enzyme digests to be a trifucosylated complex biantennary glycan containing two GalNAc-GlcNAc antennae. Although the glycan was probably a mixture of isomers, depending on the positions of fucose substitution, the MS/MS spectrum confirmed the biantennary structure. The prominent fragment at m/z 407.2 (Figure 8) corresponded to a composition of HexNAc 2 and was absent from the spectra of the hybrid structures, indicating that it did not originate from the core. Where Gal-GlcNAc chains are present, a corresponding ion at m/z 366.2 is produced from the antennae (Figure 9) . A corresponding singly charged ion at m/z 1875.9 was formed by loss of two unsubstituted HexNAc residues. It is most likely that this fragmentation occurs as a single cleavage rather than as two independent losses of single HexNAc residues thus supporting the occurrence of an unsubstituted GalNAc-GlcNAc chain. This conclusion is supported by the MS/MS spectrum of the 2AB derivative of a trifucosylated biantennary (Gal-GlcNAc containing antennae) from human parotid gland that is known to contain mainly outer arm fucose residues on the same (3) antenna (Gillece-Castro et al., 1991; Guile et al., 1998) . This compound also fragmented by cleavage at the GlcNAc residue of the antenna with loss of Gal-GlcNAc. Ions were also present in the spectrum (Figure 8 ) at m/z 553.3 and 699.3 corresponding to the compositions of (HexNAc) 2 with one and two fucose residues, respectively, thus locating two of the fucose residues to one of the antennae. The weak fragment at m/z 699.3 corresponding to a composition of HexNAc 2 Fuc 2 showed that at least some of the molecules contained two outer arm fucose residues attached to the same antenna. The location of the third fucose residue on the reducingterminal GlcNAc residue (core fucose) was indicated by the presence of the singly charged Y-type fragment ion at m/z
([GlcNAc(Fuc)-2AB H]
). MS/MS spectra of the compounds containing four HexNAc residues suggested that several isomers existed for most masses. The high content of hexose, up to seven residues, detected by MALDI MS and ESI MS in compounds of this type suggested that these compounds were hybrid structures, and this was confirmed by the fragmentation patterns. A representative spectrum is shown in Figure 9 for the compound with a composition of Hex 5 HexNAc 4 Fuc ([M 2H] 2 ion at m/z 954.9). The abundant Y-type ion at m/z 488.3 (GlcNAc[Fuc]-2AB) confirmed the presence of a core-fucose residue. This spectrum was unlike that of a reference sample of a core-fucosylated biantennary glycan, a common N-linked glycan with this composition. The most abundant fragment ion was the singly charged ion at m/z 204.1 (HexNAc). This ion, along with the fragment at m/z 1704.8 (singly charged), which corresponds to the loss of one HexNAc from the precursor ion, and the very low abundance of the ion at m/z 407.2 (GlcNAc 2 ) as compared to Figure 9 , indicates the presence of an unsubstituted terminal GlcNAc residue but absence of the GalNAcGlcNAc moiety. The ion at m/z 366.2, corresponding to Hex-HexNAc, was consistent with the presence of a terminal Hex-HexNAc group. Loss of this moiety gave the ion at m/z 1542.8. An abundant singly charged Y-type fragment at m/z 1218.6 corresponded to the loss of three hexose residues Glycosylation differences between normal and tumor RNase 1 from the ion at m/z 1704.8 (loss of HexNAc) or two hexoses from m/z 1542.8, consistent with a hybrid structure (cleavage at the core mannose). It was unclear, however, if the spectrum represented a mixture of these, or other isomers. Additional information on the structure of these glycans came from the results of the digests with ABS, AMF, BKF, BTG, SPH, and JBH ( Figure 6 ) which showed that both Man 4 -and Man 5 -containing hybrid structures were present. In addition, MALDI and ESI MS data indicated that compounds containing four HexNAc residues existed with three to seven hexose residues. This distribution would correspond to hybrid glycans with from zero to two mannose residues attached to the mannose of the 6-arm (Man 3 ±Man 5 structures) together with up to two galactose residues attached to the two noncore GlcNAc residues that comprised the 3-antenna. Thus, the fully substituted (sevenhexose-residues) glycan would contain five mannose and two galactose residues, and the least substituted compound would only contain the core mannose residues. This distribution of hexose residues confirmed the presence of two HexNAc residues on the 3-antenna and the absence of bisecting structures in at least some of these glycans.
Although the compounds with seven hexose residues must have contained two Gal-GlcNAc residues on the 3-antenna, their structures are unambiguous. However, for compounds with unsubstituted GlcNAc residues, there is the possibility that this GlcNAc residue was attached in the bisecting position between a1-3 and a1-6 arms. A fragment ion thought to be unique for the presence of bisecting GlcNAc (GlcNAc-Man-GlcNAc-GlcNAc [Fuc]-2AB) was present at m/z 1056.5 in the spectrum shown in Figure 9 , suggesting the presence of a bisect, but none of the other spectra that were examined contained an ion at this mass, strongly indicating that most contained two GlcNAc residues on the 3-antenna and no bisecting GlcNAc.
Summary of Capan-1 RNase 1 glycans HPLC, exoglycosidase digestions, and mass spectra analyses have shown that RNase 1 from Capan 1 possesses a range of complex, bisected, and hybrid N-glycans, some of which contain GalNAc residues. The main core structures, deduced by MS/MS fragmentation, were hybrid glycans with a branched 3-antenna and biantennary structures containing mainly Gal-GlcNAc chains (see Figure 10 ). Both types of compounds were substituted with up to three fucose residues and some were additionally sialylated (Table III) . Bisected biantennary structure A 2 G 2 B was deduced by exoglycosidase analysis, and their substitution Glycosylation differences between normal and tumor RNase 1 with fucoses and sialic acid was determined by LC-ESI MS ( Figure 10 and Table III) .
Oligosaccharide sequencing of RNase 1 glycans from the pancreatic adenocarcinoma cell line MDAPanc-3: RNase 1 purification As described for Capan-1, RNase 1 fractions were purified from MDAPanc-3 cell culture media, and four different glycosylated RNase1 fractions (M1±M4) were obtained (Figure 11a ). MDAPanc-3 cells secrete less RNase 1 than Capan-1 (Ferna Â ndez-Salas et al., 2000) . Although only a limited analysis was possible, the main features required to compare the glycosylation of MDAPanc-3 RNase 1 with that of Capan-1 and normal pancreas were determined using the sensitive normal phase HPLC technology (detects 10 fmole of 2AB-labeled glycans).
Characterization of oligosaccharides
As described, oligosaccharides from MDAPancE3 samples were released from gel bands by in situ digestion with PNGaseF and fluorescently labeled with 2AB. Normal phase HPLC profiles of the N-linked oligosaccharides from the different MDAPanc-3 fractions showed low levels of glycans in all fractions. The fraction containing most glycans (M2) was selected for exoglycosidase analysis.
The results of exoglycosidase digestions on the glycans from fraction M2 are shown in Figure 11b . Digestion with sialidase (ABS) suggested the presence of sialic acids, whereas fucosidase digestions indicated the presence of fucose linked a1-3 or 1-4 to the antennae and core fucose. Treatment with galactosidases (SPG and BTG) gave similar digestion products, indicating that most galactose residues were linked b1-4 to GlcNAc. The glycans obtained after galactosidase digestion are likely to be A 2 and A 2 B from their GU values, and there were also other structures of higher GU that may be hybrid glycans. The low levels of glycans precluded a rigorous analysis in these MDAPanc3 RNase 1 fractions. However, the general conclusion that can be drawn from the available data is that the major glycans are most likely to be core and outer arm fucosylated complex biantennary oligosaccharides, some of which could contain sialic acid.
Western blotting and ELISA analysis of RNase 1 fractions with antibodies against Lewis antigens Some of the major differences in the glycan structures from pancreas, Capan-1, and MDAPancE3 RNase 1 were confirmed by immunoblotting using antibodies against Lewis antigens (Figure 12) .
From the glycan sequencing data, RNase 1 glycans from both Capan-1 and pancreas contained the Lewis x antigen (Figure 12 ). However, one of the differences between them was in the type of monosaccharides attached to the outer galactose. Glycans from Capan-1 present sialic acid attached a2-3 to galactose, forming the sialyl-Lewis x antigen, and RNase 1 from pancreas contained fucose a1-2 attached to galactose, giving the Lewis y antigen. As will be discussed, these different antigens reflect significant differences in glycosyltransferases in the normal and the tumor cells. To evaluate if these glycosylation processing differences could be detected by western blotting, high (two to three occupied sites) and medium (one to two occupied sites) glycosylated RNase 1 fractions from healthy pancreas, Capan-1, and MDAPanc-3 were probed with antibodies to Lewis y , sialyl-Lewis x , and sialyl-Lewis a antigens. Glycosylated RNase 1 fractions (150±250 ng) were loaded onto an SDS±PAGE gel and transferred to a PVDF membrane. The conditions of the transfer were modified from the standard ones (Tris±glycine, pH 8.5, 20% methanol) to produce a maximum yield for the transfer. Bicarbonate-carbonate, pH 9.9, 20% methanol was used as a transfer buffer because basic proteins such as RNase and lysozyme are more efficiently transferred under conditions of high pH (data not shown).
Highly glycosylated fractions of RNase 1 from Capan-1 were positive for sialyl-Lewis x while, in contrast, most glycosylated RNase 1 fractions from pancreas were positive for Lewis y (Figure 13a, b) . MDAPanc-3 RNase 1 fractions were negative for Lewis y and sialyl-Lewis x but were immunoreactive with anti-sialyl-Lewis a antibodies (Figure 13c ). The membranes were stripped and reprobed with antiRNase 1 polyclonal antibodies to corroborate that the Lewis positive bands were from the RNase 1 fractions. These results were also confirmed by ELISA analysis: 10± 50 ng of medium and highly glycosylated fractions from pancreas were positive for Lewis y and negative for sialylLewis x or sialyl-Lewis a fractions consistent with our previous data (Ferna Â ndez-Salas et al., 2000) (data not shown). Capan-1 and MDAPanc-3 fractions were positive for sialyl-Lewis x and sialyl-Lewis a , respectively (Figures 13d, e) .
Tumor cell surface glycoconjugates of Capan-1 and MDAPanc-3 cells reacting with antibodies against sialyl-Lewis x and sialyl-Lewis a Sialylated and fucosylated antigens on the surface of pancreatic cells were examined by ELISA using antibodies against Lewis antigens. High expression levels of sialylLewis x were detected on the cell surface of both Capan-1 cells and MDAPanc-3 cells. In addition, MDAPanc-3 cells also expressed sialyl-Lewis a antigen. The Lewis structures identified on the whole cells are in agreement with those detected by ELISA and western blot of the purified RNase 1 fractions, indicating that the perturbations in the expression levels of glycan processing enzymes are not specific to RNase 1 and affect both membrane-bound and secreted glycoproteins.
Discussion
Alterations in cell surface glycosylation are common in cancer cells and arise from changes in glycosyltransferase activities or their gene expression (Kim and Varki, 1997; Dennis et al., 1999; Orntoft and Vestergaard, 1999) . Some of these glycosylation changes, in particular the expression of sialyl-Lewis x (SLe x ) and sialyl-Lewis a (SLe a ) antigens, are involved in the late stages of malignancy, including tumor invasion and metastasis. SLe x and/or SLe a epitopes are both ligands for E-and P-selectin (Fukuda, 1996; Ohyama et al., 1999) . These selectins are expressed on vascular endothelial cells and up-regulated in inflammation. Therefore SLe x and/or SLe a determinants on tumor cell surfaces may well be involved in their adhesion to vascular endothelium, mimicking the homing of leukocytes and thus contributing to hematogenous metastasis (Fukuda, 1996) .
Capan and MDAPanc-3 cells express SLe x and SLe a antigens on their cell surfaces Altered expression of carbohydrate antigens has been described in both pancreatic adenocarcinoma tissues (Kim et al., 1988; Philipsen et al., 1991; Sinn et al., 1992; Zhang et al., 1997; Nakamori et al., 1999) and in pancreatic tumor Glycosylation differences between normal and tumor RNase 1 cell lines (Mas et al., 1998; Hosono et al., 1998) . Increased expression of Lewis x , sialyl-Lewis x , and sialyl-Lewis a has been detected in pancreatic adenocarcinoma tissues (Kim et al., 1988; Sinn et al., 1992; Nakamori et al., 1999) . In normal tissues, duct cells and centroacinar cells abundantly expressed type I structures, such as Lewis a and Lewis b (Philipsen et al., 1991) , and Lewis y has been detected in both ductal and acinar cells (Philipsen et al., 1991; Kim et al., 1988) . Lewis y was also expressed in pancreatic cancers (Kim et al., 1988; Zhang et al., 1997) . Several tumor pancreatic cell lines presented an enhanced expression of sialylLewis a and sialyl-Lewis x structures on the cell surface (Mas et al., 1998; Hosono et al., 1998) . In this article, we extended these findings to MDAPanc-3 and Capan-1 cells, both metastatic pancreatic tumor cell lines, demonstrating that they express SLe x and SLe a antigens on their surfaces, too. Increased sialylation of tumor cell surface molecules is a well-known phenomena; sialic acid, typically found at the termini of sugar chains of glycoconjugates, is an important monosaccharide that can serve as ligand in important recognition phenomena such as lectin binding (Varki, 1997) . The changes in glycosyltransferase activities in tumor cells, which were apparent from the analysis of their cell surface glycosylation, were also reflected in their secreted glycoproteins, which use the same biosynthetic pathway. In this article, the analysis of the oligosaccharides attached to a pancreatic glycoprotein, RNase 1, secreted by both normal and tumor pancreatic cells (Capan-1 and MDAPanc-3), revealed two completely different glycosylation patterns. One of the most significant differences was the presence of acidic glycans in tumor RNase 1. In Capan-1 RNase 1, these charged oligosaccharides fractions, which represent about a quarter of the total glycans, were shown to contain sialic acid and gave rise to SLe x epitope. These data are consistent with the structures found by ELISA on the cell surface of these Capan-1 cells.
In contrast to RNase 1 glycans from tumor cells, Nglycans of RNase 1 from normal pancreatic cells presented a higher content of fucose and no sialic acid. These data are in agreement with the glycosylation described for glycopeptides derived from human pancreatic secretion (which includes RNase 1) that also contained high levels of fucose and no sialic acid (Yoshihara et al., 1995) . The fucosylated glycans in RNase 1 were mainly biantennary, but triantennary, tetraantennary, and some polylactosamine glycans, all extensively fucosylated, were also detected. These larger glycans, completely absent in the RNase 1 from tumor cells, were identified in the highly glycosylated fractions of pancreas RNase 1, suggesting that they are probably located at Asn-76 and/or Asn-88.
Some of these N-glycans from normal RNase 1 contained the Le y epitope because they terminated in fucose a1-2 linked to terminal galactose instead of sialic acid ( Figure  12 ). ELISA and western blotting analysis confirmed their presence. In contrast, SLe x and SLe a were detected in RNase 1 from Capan-1 and MDAPanc-3 cells, respectively ( Figure 13 ). The detection of the different epitopes in normal and tumor RNase 1 by commercially available monoclonal antibodies (mAbs) suggests that this method may be used to detect these differences in other tissues or biological fluids. Our data suggest that there is a high level of a1-2-fucosyltransferase activity in normal pancreatic cells in contrast to Capan-1 tumor cells where there is increased a2-3-sialyltransferase activity. These results agree with studies described for other human metastatic pancreatic cancer cells where it was reported that the expression of sialylLewis x and sialyl-Lewis a is regulated by a diminution of the activity of a1-2 fucosyltransferase and an increase of a1-3/a1-4-fucosyltransferases and a2-3-sialyltransferase (Mas et al., 1998; Aubert et al., 2000) .
Normal and Capan-1 pancreatic RNase 1 and N-acetylglucosaminyltransferases (GnTs) In normal RNase 1, bisected GlcNAc was present only in 10% of the complex biantennary structures. In RNase 1 from Capan-1, bisecting structures were also detected, although not quantified. Bisecting GlcNAc is attached by GnT III, and its activity is increased in pancreatic adenocarcinoma (Nan et al., 1998) , together with that of GnT IV and V. These authors also showed that RNase 1 from pancreatic cancer patient serum bound to wheat germ agglutinin lectin more than serum RNase 1 from healthy donors, suggesting that the tumor RNase 1 glycans contained an increased level of bisecting GlcNAc.
Other N-glycans from Capan-1 contained hybrid structures with two antennae on the 3-arm that would arise from the activity of GnT IV that is also increased in human pancreatic adenocarcinoma (Nan et al., 1998) . Increased glycan branching is a common feature of malignant cells and leads to further termini that can be sialylated.
Capan-1 RNase 1 has N-linked glycans containing b-linked GalNAc Some of the tumor N-glycan structures contain b-linked GalNAc. The carbohydrate attachment of this oligosaccharide is controlled by b1-4-N-acetylgalactosaminyl transferase activity, and it is not commonly found in N-glycans. However, it has been identified in the glycoproteins from the pituitary gland (Green et al., 1985; Green and Baenziger, 1988; Chan et al., 1991; Van-denEijnden et al., 1995) and from other vertebrate sources, such as bovine milk, rat prolactin, or kidney epithelial cells (Varki et al., 1999) . b-linked GalNAc has also been reported in melanoma tissues (Chan et al., 1991; Kuo et al., 1998) , suggesting that the expression of this carbohydrate is related to a malignant transformation.
We have shown that in pancreatic cancer, both cell surface glycoproteins and secreted RNase 1 are aberrantly glycosylated. Glycan processing is cell typeEspecific; therefore other glycoproteins secreted from pancreatic tumors would also be expected to show disease-associated glycosylation changes. The results presented in this article offer the possibility of distinguishing between a normal pancreas and one containing a tumor by detecting the altered glycosylation of circulating glycoproteins. Elevated serum levels of RNase 1 are not specific enough to be used as a marker for pancreatic carcinoma (Reddi and Holland, 1976; Weickman et al., 1984; Kurihara et al., 1984; Kemmer et al., 1991; Kobayashi et al., 1994; Tabare Âs, 2000) . The tumor-associated glycosylation changes in glycoproteins, such as RNase 1, which is secreted and shed into the blood stream, may be detected by mAbs or lectins against specific carbohydrate epitopes, such as SLe x and SLe a , opening a new way of using this protein as a tumor marker of pancreatic cancer.
Material and methods
RNase 1 purification from pancreas Human pancreases were obtained from healthy donors (kindly donated from Unitat de Transplantament Hepa Á tic from Hospital Vall d'Hebron, Barcelona) and at autopsy through the Hospital Josep Trueta, Girona. In both cases, they were immediately frozen and stored at ±80 C. Ribonuclease was extracted by the method of Weickmann et al. (1981) with the following modifications. Briefly, pancreases were homogenized with 0.25 M sulfuric acid and spun at 20,000 rpm at 4 C for 20 min. The supernatant was adjusted to pH 8 with concentrated NH 4 OH, and protease inhibitors were added to final concentrations of 10 mg/ml for leupeptin, 5 mM for phenylmethylsulfonyl fluoride (PMSF), 1% for aprotinin, and 5 mM for ethylenediamine tetraacetic acid. This neutral supernatant was subjected to acetone precipitation, and RNase 1 fractions were collected between 33% and 66% acetone and were dissolved with 50 mM Tris± HCl, 20 mM NaCl, pH 7. Protease inhibitors were added to final concentrations of 5 mg/ml for leupeptin and 5 mM for PMSF.
RNase 1 fractions were further purified by two chromatographic steps: HiTrap Heparin column (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK) and Vydac C4 (Vydac, Hesperia, CA) reversed-phase chromatography. The HiTrap Heparin column was preequilibrated with 50 mM Tris±HCl, 20 mM NaCl, pH 7 before sample injection. The column was eluted with 20 column volumes of a linear NaCl gradient (0.02±0.6 M) followed by 10 column volumes of a second linear NaCl gradient (0.6±1.5 M). Ribonuclease fractions were eluted between 0.375 and 0.75 M NaCl, dialyzed against MilliQ water, and freezedried. Reversed-phase chromatography with a Vydac C4 column was carried out as described previously .
RNase 1 purification from conditioned cell media Capan-1 (American Type Culture Collection no. HTB-79) and MDAPanc-3 cell lines (Frazier et al., 1990) were cultured in 10% synthetic serum basal medium supplement (Seromed/Biochrom KG, Berlin, Germany). These cells were adapted to grow in this medium following the protocol described by Ferna Â ndez et al. (1994) .
RNase 1 was purified from the conditioned media of Capan-1 and MDAPanc-3 cultures using a modification of the protocol of Ferna Â ndez- Salas et al. (2000) . At the first step of purification, instead of an anionic-exchange column (DEAE-Sepharose CL-6B, Amersham Pharmacia Biotech), the concentrated media were loaded in a HiTrap Heparin column in an HPLC system (AKTA, Amersham Pharmacia) as described for RNase 1 purification from pancreas. The next two chromatographic steps, cationic exchange on a MONO-S HR 5/5 column (Amersham Pharmacia Biotech) and reversed-phase on a Vydac C4 column, were performed following the protocol described previously (Ferna Â ndezSalas et al., 2000) . After each chromatographic step, ribonuclease activity and sample purity were checked by zymography and by SDS±PAGE with silver staining (Blum et al., 1987) , respectively.
Release and purification of N-linked oligosaccharides N-glycans were released from purified ribonuclease 1 fractions by in situ digestion of the protein in SDS±PAGE gel bands with N-glycosidase F (PNGase F, Roche, Mannheim, Germany) as described earlier (Ku È ster et al., 1997) . Briefly, purified ribonuclease fractions were separated by electrophoresis under reducing conditions and visualized by Coomassie staining. Bands containing the glycoprotein were excised from the gel, reduced, alkylated, and treated with PNGase F to release the N-linked glycans. Wide-range molecular markers were from Sigma, (Pool, Dorset, UK).
Fluorescent labeling of the reducing terminus of oligosaccharides Oligosaccharides were fluorescently labelled with 2AB by reductive amination (Bigge et al., 1995) using the Oxford GlycoSciences Signal labelling kit (OGS, Abingdon, Oxon, UK).
HPLC
Normal-phase HPLC was performed using a TSK-Gel Amide-80 4.6 mm Â 250 mm column (Tosoh Biosep LLC, Montgomeryville, PA) on a 2690 Alliance separations module (Waters, Milford, MA) equipped with a Waters temperature control module and a Waters 474 fluorescence detector. Solvent A was 50 mM formic acid adjusted to pH 4.4 with ammonia solution. Solvent B was acetonitrile. The column temperature was set to 30 C. Gradient conditions were a linear gradient of 20±58% A, over 152 min at a flow rate of 0.4 ml/min. Samples were injected in 80% acetonitrile. Fluorescence was measured at 420 nm with excitation at 330 nm. The system was calibrated using an external standard of hydrolyzed and 2AB-labeled glucose oligomers to create a dextran ladder, as described previously (Guile et al., 1996) .
Weak anion-exchange HPLC (Guile et al., 1994) was performed using a Vydac 301VHP575 7.5 Â 50 mm column (Anachem, Luton, Bedfordshire, UK) according to the modified methodology described by Zamze et al. (1998) . Briefly, solvent A was 0.5 M formic acid, adjusted to pH 9 with ammonia solution. Solvent B was 10% (v/v) methanol in water. Gradient conditions were a linear gradient of 0±5% A over 12 min at a flow rate of 1 ml/min, followed by 5±21% A over 13 min, then 21±50% A over 25 min, 80± 100% A over 5 min, then 5 min at 100% A. Samples were injected in water.
Simultaneous oligosaccharide sequencing by exoglycosidase digestions All enzymes were purchased from Glyko (Novato, CA). The 2AB-labeled oligosaccharides were digested in a volume of 10 ml for 18 h at 37 C in 50 mM sodium acetate buffer, pH 5.5, using arrays of the following enzymes: ABS (EC 3.2.1.18), 1 U/ml; Newcastle disease virus neuraminidase (EC 3.2.1.18), 200 mU/ml; AMF (EC 3.2.1.111), 3 mU/ ml; BKF (EC 3.2.1.51), 1 U/ml; SPG (EC 3.2.1.23), 0.1 U/ ml; BTG (EC 3.2.1.23), 1 U/ml; SPH (EC 3.2.1.30), 120 mU/ml; JBH (EC 3.2.1.30), 10 mU/ml; and jackbean amannosidase (EC 3.2.1.24), 50 U/ml. After incubation, enzymes were removed by filtration through a protein binding nitrocellulose membrane (Pro-Spin 45 mm CN filters, Radley and Co., Essex, UK) and oligosaccharides were analyzed by normal phase HPLC.
For incubations with jack bean a-mannosidase, the enzyme was added, incubated overnight, and then a second aliquot was added and incubated for a further 8 h. The enzyme was then denatured by boiling for 5 min, the sample was spun, and the supernatant was analyzed by normal phase HPLC.
MALDI-TOF MS
Positive ion MALDI-TOF mass spectra were recorded with a Micromass TofSpec 2E reflectron-TOF mass spectrometer (Micromass, Manchester, UK) fitted with delayed extraction and a nitrogen laser (337 nm). The acceleration voltage was 20 kV; the pulse voltage was 3200 V; and the delay for the delayed extraction ion source was 500 ns. Samples were prepared by adding 0.5 ml of an aqueous solution of the sample to the matrix solution (0.3 ml of a saturated solution of 2,5-dihydroxybenzoic acid in acetonitrile) on the stainless steel target plate and allowing it to dry at room temperature. The sample/matrix mixture was then recrystallized from ethanol (Harvey, 1993) .
HPLC LC-ESI MS
LC-ESI MS data were obtained with a Waters CapLC HPLC system interfaced with a Micromass hybrid quadrupole time-of-flight mass spectrometer fitted with a Z-spray electrospray ion source and operated in positive ion mode. A 1 Â 150 mm microbore normal phase HPLC column was packed with stationary phase material from a GlycoSep N column (Oxford GlycoSciences, Abingdon, Oxon, UK). The operating conditions for the mass spectrometer were as follows: source temperature 100 C; desolvation temperature 120 C; desolvation gas flow 200 L/h; capillary voltage 3000 V; cone voltage 30 V; TOF survey scan time 1 s, mass range m/z 50±2300; TOF tandem mass spectrometry (MS/ MS) scan time 1 s, survey scan 950±1600 with detection mass range m/z 50±3500; and mass selection resolution about 3 Da. The MS to MS/MS automatic switching was initiated when the nominated peak intensity rose above 4. Switching back to MS mode occurred after 30 s or when the peak intensity fell below 1. The mass of this peak was then ignored by the automatic switching routine for 30 s. An automatic collision energy (CE) profile was used with CEs of 14±32 V. Results from the different collision energies were combined for data evaluation. N-glycan analysis by ELISA and western blotting mAbs F3 (anti-Lewis y ) and KM-93 (anti-sialyl-Lewis x ) were from Calbiochem (Darmstadt, Germany). The mAb against sialyl-Lewis a was a generous gift from C. de Bolo Â s (Bolo Â s et al., 1995) . Peroxidase-conjugated goat anti-mouse immunoglobulins, IgG IgM, was from Jackson Immunoresearch Laboratories (West Grove, PA). Polyclonal antibodies against human recombinant RNase 1 were obtained by standard procedures .
ELISA. 10±50 ng of purified samples, classified according to their glycosylation (highly glycosylated, 2±3 occupied sites, and medium-low glycosylated, 1±2 occupied sites), were bound overnight at 4 C to 96-well polystyrene plates in carbonate/bicarbonate buffer, pH 9.6. After washing twice with saline (0.9% NaCl solution)±Tween 0.05%, plates were blocked with 1% nonfat milk, 0.05% (v/v) Tween in phosphate buffered saline (PBS) for 1 h at room temperature. The wells were then washed once with saline±Tween 0.05% and were incubated for 2 h at room temperature with the above primary MAbs at 1/50 dilution in PBS, 0.05% Tween, except for anti-sialyl-Lewis a (1/2 dilution). Plates were washed four times with saline±Tween 0.05% and the second antibody, peroxidase-conjugated goat anti-mouse antiserum 1:2000 in PBS, 0.05% Tween, was added and allowed to stand for 1 h at room temperature. Plates were washed again four times with saline±Tween 0.05%, and detection was performed using a chemiluminescence kit (SuperSignal West Dura, Pierce, Rockford, IL) in an automated chemiluminescence reader (Roche). Data are expressed as the mean AE SD of assays performed in triplicate. Negative controls were wells without antigen, or without the first antibody, and wells with lysozyme as antigen.
Western blotting. Analyses of Lewis antigens were performed following standard western blot protocols. Briefly, RNase 1 fractions were pooled in high and medium glycosylated fractions, electrophoresed in a 15% SDS±PAGE gel and transferred to a polyvinylidine difluoride membrane (Roche). The transfer buffer was 3 mM carbonate/10 mM bicarbonate, pH 9.9, 20% methanol. The transfer was performed at 100 V for 3 h. Filters were blocked in 3% (w/v) nonfat milk, 0.1% Tween in Tris-buffered saline and incubated for 2 h with anti-sialyl Lewis x (1/50), anti-Lewis y (1/ 50), or anti-sialyl Lewis a (1/2) in blocking buffer. Secondary antibody, peroxidase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Labs) was added at 1/8000 and incubated for 1 h. Detection was performed using a chemiluminescence kit.
Cell ELISA Capan-1 (ATCC no. HTB-79) and MDAPanc-3 cell lines (Frazier et al., 1990) were cultured to 90% confluence in Dulbecos's modified Eagle's medium supplemented with 10% fetal bovine serum. Cells were seeded on a 96-wells plate at a concentration of 10 4 cells/well and allowed to grow to confluence. After the cells had been washed three times with PBS (pH 7.2), they were fixed with 2% formaldehyde in PBS for 20 min at room temperature. The assay was carried out following the protocol described by Zhou et al. (1991) . Briefly, after washing with PBS and blocking the plate wells with 1% bovine serum albumin in PBS, specific mouse mAbs against carbohydrates (anti-sialyl-Lewis x or anti-sialyl-Lewis a at 1/50 and 1/2 dilutions, respectively, in 1% bovine serum albumin in PBS) were added and incubated for 2 h at room temperature. The wells were then washed and incubated with the secondary antibody, peroxidase-conjugated goat anti-mouse IgG 1/2000 diluted in 1% bovine serum albumin in PBS for 1 h at room temperature. The assay was developed with 100 ml/well of 3,3 H ,5,5 H -tetramethylbenzidine (BM BluePOD substrate soluble, Roche). The reaction was stopped with 100 ml/well of 1 M H 2 SO 4 , and the absorption was measured at 450 nm (against a reference wavelength of 630 nm) in an automated microplate reader (BIO-TEK, Winooski, VT). As negative controls, highly differentiated breast carcinoma cells MCF-7 (Soule et al., 1973) were used together with plates containing wells without primary or secondary antibodies.
